Overview Goal and Objectives The goal of this resource is to support an increasing number of high quality, innovative, investigator-initiated early-phase clinical trials by providing experienced research nursing and data management support exclusively for the management of these trials. The availability of this research support is essential for trials that have high levels of complexity, high demand for specimens, and/or increased need for patient surveillance and interactions. Patients entered onto these predominantly Phase I or Phase I/II trials will have increased need for specialized research nursing to insure that 1) all consent is particularly well informed;2) all adverse events are detected;3) all requisite samples are obtained at the appropriate time and with expeditious and careful processing;and 4) feedback to and from the patients is maintained at an optimal level. Investigators making use of this facility will have the availability of the Cancer Center Shared Resources for tissue and genetic analyses, enabling clinical investigators without their own laboratories to initiate investigator-initiated protocols that include correlative studies. Rationale Stanford's Developmental Therapeutics group and their activities within the Molecular Therapeutics Program have been expanding. The vision over the next five years is to make early-phase clinical/translational research built on Stanford science the highest priority of the Cancer Center. The Freidenrich Center for Translational Research, to be completed in 2012, will be dedicated to this mission and will provide integrated space for patient treatment, research nursing support, and data management in a single location. This physical proximity, together with Dr. Sikic's (Associate Director Clinical Research;05: Therapeutics) leadership and recent, anticipated recruitments in the areas of translational medicine and Phase I/II trial capability, will provide an ideal environment for the expansion of the early phase cancer clinical trial program.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
United States
Zip Code
Ganjoo, Kristen; Hong, Fangxin; Horning, Sandra J et al. (2014) Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404). Leuk Lymphoma 55:768-72
Chiou, Shin-Heng; Kim-Kiselak, Caroline; Risca, Viviana I et al. (2014) A conditional system to specifically link disruption of protein-coding function with reporter expression in mice. Cell Rep 7:2078-86
Zhu, Gefei Alex; Danial, Christina; Liu, Andy et al. (2014) Overall and progression-free survival in metastatic basosquamous cancer: a case series. J Am Acad Dermatol 70:1145-6
Caswell, Deborah R; Chuang, Chen-Hua; Yang, Dian et al. (2014) Obligate progression precedes lung adenocarcinoma dissemination. Cancer Discov 4:781-9
Bartroff, Jay; Lai, Tze Leung; Narasimhan, Balasubramanian (2014) A new approach to designing phase I-II cancer trials for cytotoxic chemotherapies. Stat Med 33:2718-35
Kohrt, Holbrook E; Thielens, Ariane; Marabelle, Aurelien et al. (2014) Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123:678-86
DiCarlo, Joseph; Agarwal-Hashmi, Rajni; Shah, Ami et al. (2014) Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 20:361-9
Chang, Serena; Kohrt, Holbrook; Maecker, Holden T (2014) Monitoring the immune competence of cancer patients to predict outcome. Cancer Immunol Immunother 63:713-9
Ansari, Celina; Tikhomirov, Grigory A; Hong, Su Hyun et al. (2014) Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy. Small 10:566-75, 417
Lavori, Philip W; Dawson, Ree (2014) Introduction to dynamic treatment strategies and sequential multiple assignment randomization. Clin Trials 11:393-399

Showing the most recent 10 out of 24 publications